Compare AVNW & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNW | CCCC |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.4M | 240.3M |
| IPO Year | 2007 | 2020 |
| Metric | AVNW | CCCC |
|---|---|---|
| Price | $21.88 | $2.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $32.50 | $8.50 |
| AVG Volume (30 Days) | 112.0K | ★ 1.7M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $453,497,000.00 | $30,108,000.00 |
| Revenue This Year | $5.73 | N/A |
| Revenue Next Year | $6.79 | N/A |
| P/E Ratio | $20.97 | ★ N/A |
| Revenue Growth | ★ 10.72 | N/A |
| 52 Week Low | $15.80 | $1.09 |
| 52 Week High | $26.83 | $4.89 |
| Indicator | AVNW | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 51.91 |
| Support Level | $20.81 | $2.49 |
| Resistance Level | $21.38 | $2.84 |
| Average True Range (ATR) | 0.89 | 0.19 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 56.81 | 52.72 |
Aviat Networks Inc is a networking solutions provider. It designs, manufactures and sells wireless networking products, solutions, and services to mobile and fixed operators, private network operators, government agencies, transportation and utility companies, public safety agencies, and broadcast network operators around the world. The company's product categories include point-to-point microwave and millimeter wave radios that are licensed (subject to local frequency regulatory requirements), lightly licensed and license-exempt (operating in license-exempt frequencies), and element and network management software.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.